Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06515015

Evaluation of the Feasibility, Safety, and Efficacy of Single-use Endobronchial Silicon Spigots for the Treatment of Refractory Pneumothorax

Study Objective: To evaluate the feasibility and safety of the disposable endobronchial silicon spigots for treating refractory pneumothorax and to preliminarily assess its efficacy, providing domestic experience for the development and clinical application of bronchial occlusion.

Study Population: Patients intended to receive selective bronchial occlusion technology for the treatment of refractory pneumothorax.

Sample Size: This study is a preliminary exploration of the application value of the disposable endobronchial silicon spigots occlusion technology in refractory pneumothorax. The sample size has not been strictly calculated, and it is expected to include 10 patients.

Study Design: This study is an exploratory, single-group, single-center clinical study.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Second Affiliated Hospital of Fujian Medical University

Quanzhou, Fujian, 362018, China

Location status: Recruiting

Location contact

Yiming Zeng, M.D

CONTACT

[email protected]

+86 13515042402

Yiming Zeng, M.D

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects must meet all of the following criteria to be enrolled:
  • Male or female, aged ≥18 years;
  • Patients with various types of pneumothorax who still have persistent air leaks after continuous intercostal drainage for 7 days;
  • After evaluation by the researcher, the subject is feasible for the bronchoscopic procedure of selective bronchial occlusion to treat refractory pneumothorax, and the responsible bronchus can be determined by the balloon detection;
  • Voluntarily participate in this trial and sign an informed consent form.

Exclusion criteria

  • Subjects with any of the following conditions cannot be selected:
  • Allergic to silicone materials;
  • Contraindications for bronchoscopy:
  • Myocardial infarction within the past month;
  • Active massive hemoptysis;
  • Platelet count <20×10^9/L;
  • Pregnancy;
  • Malignant arrhythmias, unstable angina, severe cardiopulmonary dysfunction, hypertensive crisis, severe pulmonary arterial hypertension, intracranial hypertension, acute cerebrovascular events, aortic dissection, aortic aneurysm, severe mental illness, and extreme systemic exhaustion, etc.
  • Uncontrolled acute pulmonary infection or severe chronic infection at the intended occlusion lobes or segments;
  • Obvious hemodynamic instability or unstable respiratory failure;
  • The responsible bronchus cannot be determined by balloon detection;
  • The researcher believes that the patient has other conditions that are not suitable for inclusion in this study.

Treatment and study plan

Endobronchial Silicon Spigots

Device

The single-use endobronchial silicon spigot is injection-molded from implant-grade silicone and has a solid conical body. The endobronchial silicon spigot is used for the temporary occlusion of the target bronchus. It is delivered to the target bronchus through a bronchoscope using biopsy forceps, and the position of the blocker is adjusted to occlude the responsible bronchus leading to the pleural air leakage.

Primary outcomes

  1. Total Occlusion Success Rate

    Time frame: 7 days

    The percentage of subjects who are successfully* occluded after temporary embolization with endobronchial silicon spigots (including second occlusion) out of the total number of subjects receiving bronchial blocker treatment.

Secondary outcomes

  1. First Occlusion Success Rate

    Time frame: 14 days

    The percentage of subjects who are successfully occluded after the first endobronchial silicon spigots treatment out of the total number of subjects receiving endobronchial silicon spigots treatment; if a second occlusion is received within 7 days after surgery, it is not counted as a first occlusion success.

  2. First Occlusion Cure Rate

    Time frame: 14 days

    The percentage of subjects whose chest drainage tube completely stops leaking air within 14 days after the first endobronchial silicon spigots treatment out of the total number of subjects receiving endobronchial silicon spigots treatment; if a second occlusion is received within 14 days after surgery, it is not counted as a first occlusion cure.

  3. Total Occlusion Cure Rate

    Time frame: 42 days

    The percentage of subjects whose chest drainage tube completely stops leaking air within 14 days after endobronchial silicon spigots treatment (including second occlusion) out of the total number of subjects receiving endobronchial silicon spigots treatment.

  4. Chest Drainage Tube Removal Rate

    Time frame: 28 days

    The percentage of subjects who successfully remove the chest drainage tube within 28 days after endobronchial silicon spigots treatment (including second occlusion) out of the total number of subjects receiving endobronchial silicon spigots treatment.

  5. Endobronchial spigots Removal Time

    Time frame: 30 days

    The time (in days) from successful placement of the endobronchial silicon spigots to successful removal of the endobronchial silicon spigots.

  6. Technical Success Rate

    Time frame: 30 days

    The proportion of successful placements of the endobronchial silicon spigots into the responsible drainage bronchus out of the total number of operations.

  7. Incidence of Treatment-Emergent Adverse Events

    Time frame: 30 days

    Record all adverse events during surgery and postoperative follow-up, assess the relatedness to the device itself and treatment, and calculate the incidence of device-related and surgical treatment-related adverse events and serious adverse events.

Study contacts

Contact information is provided by the study sponsor or research team.

Liheng Xie

CONTACT

[email protected]

+86-13916444591

Sponsors and collaborators

Lead sponsor

Hangzhou Broncus Medical Co., Ltd.

Industry

Registry information

Official study title

Exploratory, Single-Group, Single-Center Clinical Study to Evaluate the Feasibility, Safety, and Efficacy of Single-use Endobronchial Silicon Spigots for the Treatment of Refractory Pneumothorax

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jul 23, 2024
Registry last updated
Aug 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.